Resultados globales: 2 registros encontrados en 0.02 segundos.
Artículos, Encontrados 2 registros
Artículos Encontrados 2 registros  
1.
11 p, 542.8 KB A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer / Reynolds, Kerry Lynn ; Bedard, Philippe L. (Toronto, ON Canada) ; Lee, Se-Hoon (Seoul, Republic of Korea) ; Lin, Chia-Chi (Taipei, Taiwan) ; Tabernero, Josep (Hospital Universitari Vall d'Hebron) ; Alsina, Maria (Hospital Universitari Vall d'Hebron) ; Cohen, Ezra (La Jolla, CA USA) ; Baselga, José (New York, NY USA) ; Blumenschein, George (Houston, TX USA) ; Graham, Donna M. (Toronto, ON Canada) ; Garrido-Laguna, Ignacio (Salt Lake City, UT USA) ; Juric, Dejan (Fruit Street, Boston, MA 02114 USA) ; Sharma, Sunil (Salt Lake City, UT USA) ; Salgia, Ravi (Duarte, CA USA) ; Seroutou, Abdelkader (Basel, Switzerland) ; Tian, Xianbin (East Hanover, NJ USA) ; Fernandez, Rose (East Hanover, NJ USA) ; Morozov, Alex (New York, NY USA) ; Sheng, Qing (Cambridge, MA USA) ; Ramkumar, Thiruvamoor (East Hanover, NJ USA) ; Zubel, Angela (Basel, Switzerland) ; Bang, Yung-Jue (Seoul, Republic of Korea) ; Universitat Autònoma de Barcelona
Human epidermal growth factor receptor 3 (HER3) is important in maintaining epidermal growth factor receptor-driven cancers and mediating resistance to targeted therapy. A phase I study of anti-HER3 monoclonal antibody LJM716 was conducted with the primary objective to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE), and dosing schedule. [...]
2017 - 10.1186/s12885-017-3641-6
BMC Cancer, Vol. 17 (september 2017)  
2.
10 p, 426.6 KB A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies / Spreafico, A. (University of Toronto. Princess Margaret Cancer Centre. Division of Medical Oncology and Hematology (Canada)) ; Delord, J. P. (Institut Claudius Regaud (France)) ; Mattos Arruda, Leticia de (Hospital Universitari Vall d'Hebron) ; Berge, Y. (Institut Claudius Regaud (France)) ; Pérez Rodon, Jordi (Hospital Universitari Vall d'Hebron) ; Cottura, E. (Institut Claudius Regaud (France)) ; Bedard, P. L. (University of Toronto. Princess Margaret Cancer Centre. Division of Medical Oncology and Hematology (Canada)) ; Akimov, M. (Novartis Pharma AG (Switzerland)) ; Lu, H. (Novartis Pharmaceuticals Corp (USA)) ; Pain, S. (Novartis Pharmaceuticals Corp (USA)) ; Kaag, A. (Novartis Pharma AG (Switzerland)) ; Siu, L. L. (University of Toronto. Princess Margaret Cancer Centre. Division of Medical Oncology and Hematology (Canada)) ; Cortés Castán, Javier (Hospital Universitari Vall d'Hebron) ; Universitat Autònoma de Barcelona
Heat-shock protein 990 (HSP990) is a potent and selective synthetic small-molecule HSP90 inhibitor. The primary objectives of this phase I first-in-human study were to determine dose-limiting toxicities (DLTs), maximum-tolerated dose (MTD) and recommended phase II dose (RP2D). [...]
2015 - 10.1038/bjc.2014.653
British Journal of Cancer, Vol. 112 (February 2015) , p. 650-659  

Vea también: autores con nombres similares
1 Bedard, P. L.
1 Bedard, Philippe L.
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.